Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 25, 2024 08:00 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology...
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
September 09, 2024 17:15 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology...
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
September 09, 2024 16:05 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology...
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
August 28, 2024 08:30 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology...
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024 08:30 ET
|
Aprea Therapeutics
Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 – no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash...
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
June 21, 2024 08:00 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology...
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
June 17, 2024 08:30 ET
|
Aprea Therapeutics
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet...
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
May 28, 2024 08:45 ET
|
Aprea Therapeutics
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial...
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
May 14, 2024 08:30 ET
|
Aprea Therapeutics
U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024 First-in-class...
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
May 13, 2024 16:01 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through...